Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? - Wikidata - awgldk - TriplyDB

Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

http://www.wikidata.org/entity/Q38005257

about

Role of multiparametric magnetic resonance imaging in early detection of prostate cancer Active surveillance and focal therapy for low-intermediate risk prostate cancer Histological outcomes after focal high-intensity focused ultrasound and cryotherapy Grading of prostatic adenocarcinoma: current state and prognostic implications Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer.5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT)Gleason 6 Prostate Cancer: Translating Biology into Population Health.Serum markers in prostate cancer detection Low-grade prostate cancer diverges early from high grade and metastatic disease.Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.Increased prostate cancer specific mortality following radical prostatectomy in men presenting with voiding symptoms-A whole of population study.Pathological characteristics of low risk prostate cancer based on totally embedded prostatectomy specimens.Methylome-wide Sequencing Detects DNA Hypermethylation Distinguishing Indolent from Aggressive Prostate Cancer Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome.Should Gleason 6 be labeled as cancer?The Treatment of Localized Prostate Cancer in Everyday Practice in Germany Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.Radical Prostatectomy Findings in White Hispanic/Latino Men With NCCN Very Low-risk Prostate Cancer Detected by Template Biopsy.Active surveillance for prostate cancer A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer Are the Pathological Characteristics of Prostate Cancer More Aggressive or More Indolent Depending upon the Patient Age?Defining the threshold for significant versus insignificant prostate cancer.Nationwide prevalence of lymph node metastases in Gleason score 3 + 3 = 6 prostate cancer.Management of low risk prostate cancer-active surveillance and focal therapy.Key papers in prostate cancer.Focal cryotherapy of localized prostate cancer: a systematic review of the literature.Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential.Gleason and Fuhrman no longer make the grade.Tumor volume in insignificant prostate cancer: Increasing the threshold is a safe approach to reduce over-treatment.The challenging landscape of medical device approval in localized prostate cancer.Changes in prostate cancer grading: Including a new patient-centric grading system.Prostate cancer: from Gleason scoring to prognostic grade grouping.GNL3 and SKA3 are novel prostate cancer metastasis susceptibility genes.Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading - a matched-pair analysis.Does true Gleason pattern 3 merit its cancer descriptor?Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease.

P2860

Q26768765-0E381C01-6AEA-4234-9E48-5FFB809A37E0 Q26773641-0823C410-2BDA-4D3C-A4B5-68E7D684123A Q26820469-049282A9-C5D1-49AD-8564-8AB643DAFBBC Q28066111-E29F10AC-E69F-4B93-BBB3-CC8445407372 Q33707381-760F27E0-6C8D-47CE-B1DD-3C9F02F50C74 Q34005866-1953A684-DA14-4A99-824D-6A5F6A1228AA Q34306878-DB96DC6D-0967-4E2C-B156-E83601053E3E Q34470640-B99F73E8-B5DD-410C-8528-D0CD138739C4 Q35042519-2CEC2F08-001D-4E68-9EBA-024D2C9A75E8 Q35180364-A62B6B9A-1885-413D-985A-B129A79021E4 Q35678391-974D35CB-ACE9-4693-AC2D-5F20ADAE57D5 Q35854235-2874A2D7-6969-4FF9-A9AC-7AAF4369F2E8 Q36106227-14C42BB3-E6D9-4DAA-80E5-D37C7C292407 Q36181965-08AB423C-5C17-4936-B84A-B2D2DEF7D912 Q36386969-3CBE0B1D-38F3-4771-B4DE-297B5C9434E7 Q36898434-1C5C8953-AB64-4880-AAE4-D41148D15C44 Q36931932-E586F4DF-D0F3-43BB-964A-8DA3CEE27079 Q36996753-37196F21-93F3-403D-B20C-0FF015DD9D02 Q37029385-D156AAE9-A4EC-4936-9C5F-E1402395FE35 Q37105390-16063E0E-FD51-42A9-8AFB-BB6845FDBECB Q37138594-D5D58D4C-8AD2-4F7B-B422-4E3E70572A18 Q37213040-A3E44845-892E-4A11-8506-6BBB94B3FAD0 Q37260055-F6DFA6D4-4CF2-4251-BB47-02B829588902 Q37654357-02BAD2BF-D5C2-43B7-AFE8-DDC287507427 Q38109810-CD28174C-56DD-4F55-A4A8-A738B585D0AB Q38209526-F362D211-B210-4BD2-B83A-B7BB4D99E5E3 Q38211360-A3A59DD8-24B5-49B8-98E2-6642FACDCD24 Q38263031-5A7ED3BF-8F72-4C3A-9FEE-72C9F83D2C6C Q38264786-3922C960-0666-4618-AD78-01C6D64D32AC Q38374235-1A1310E8-ED6C-4FD8-8AFB-F6514C8BB25D Q38565256-11F81F5A-C94E-4A31-AF55-0B8C58940137 Q38568583-A88C6317-480A-4EDD-B327-52F50C7DC949 Q38668993-1F85EB77-B529-4AAB-959E-E2FB55017016 Q38680873-B589F038-420B-4936-AD38-46653482AAD8 Q38786316-556E7153-0DE0-42F6-9315-29B79E10547A Q38830853-EFC91357-3198-46F5-A838-7406F1AE114F Q38846321-7819E983-7887-405F-8167-AD38AAD46094 Q38914766-DB908C45-3032-49CD-919B-4C23A33FDEC1 Q38928930-A5003F24-98F8-45C5-B6E7-846426723C16 Q39023426-FBF4A469-6134-4585-A402-7F6A2C376CBD

P2860

Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

http://www.wikidata.org/entity/Q38005257

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Do adenocarcinomas of the pros ...... to metastasize to lymph nodes?

@en

type

label

Do adenocarcinomas of the pros ...... to metastasize to lymph nodes?

@en

prefLabel

Do adenocarcinomas of the pros ...... to metastasize to lymph nodes?

@en

P1433

Q38005257-F5E7BB6F-DEAA-4023-B45B-024E1C1D9EEE

P1476

Q38005257-D0C17154-C8C7-4474-9E97-FA479556AA5D

P2093

Q38005257-5D1C8D9A-9E95-4F4F-81DE-335FCCC0232B

Q38005257-634C0611-0A38-4E7D-85E1-7863372FDADD

Q38005257-859AA127-57CA-40A4-BEF4-676573C44415

Q38005257-DB15135B-7C80-43A2-82C8-D167A1B518EA

Q38005257-E0225DE9-318C-4219-A1A1-2C85A35A58F3

Q38005257-E6823B41-9A30-452B-8BBA-8DC190050EF9

P2860

Q38005257-14D03EA6-B1EC-4D42-8B1F-8C69241D1993

Q38005257-1AFB35BC-B148-4EA2-BC40-5CD1DE5C1BFD

Q38005257-2BDCE922-857F-4D63-B6CD-27F12F3FD393

Q38005257-2D17D85F-53D7-4F7E-96F7-5E18E1E415EE

Q38005257-45699211-DDE3-4B22-9B7C-9914AAF207E1

Q38005257-4B18A722-A91A-488F-A5B0-68672A50288F

Q38005257-5861ACB4-DD78-4D5D-8D74-8595E9FC37BF

Q38005257-62384360-4B1E-43D9-87C2-A5878C3B3FA9

Q38005257-6397F414-E2F5-4321-BBA1-A88FBA50462E

Q38005257-6E74F859-CF16-4BB6-8289-AB2205AB3EFE

P304

Q38005257-3B720094-221E-4C3C-AE06-EA65F198BF46

P31

Q38005257-F33FB900-D7B0-48CF-9C18-107B7CC31A88

P356

Q38005257-8D060BFA-5967-4ACA-9229-396735A05E1F

P407

Q38005257-C0F0C1B2-A16B-4B4E-B4E6-60A14F43EE89

P433

Q38005257-7FB3A1B8-814A-47C1-A916-23C143258786

P478

Q38005257-26858703-CCD1-4F03-B318-62B73B11262C

P577

Q38005257-AD2A2AF7-7550-49F3-8D6A-158176D2D075

P698

Q38005257-ACE7382A-4519-4240-8006-C7C252013B33

P921

Q38005257-10F91AFF-649A-46FE-A049-3A7F1EBC4C22

Q38005257-F00C5AF7-013B-4AE3-8DC6-F86D53273E24

P932

Q38005257-DD51AED3-16D6-47DE-976A-ADCD6BA12B82

P356

PAS.0B013E3182556DCD

P1433

The American Journal of Surgical Pathology

P1476

Do adenocarcinomas of the pros ...... to metastasize to lymph nodes?

@en

P2093

Hillary M Ross

http://www.w3.org/2001/XMLSchema#string

Janet E Cowan

http://www.w3.org/2001/XMLSchema#string

Jeffry P Simko

http://www.w3.org/2001/XMLSchema#string

Jonathan I Epstein

http://www.w3.org/2001/XMLSchema#string

Oleksandr N Kryvenko

http://www.w3.org/2001/XMLSchema#string

Thomas M Wheeler

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of data errors in clinical research databases.

Histologic grading of prostate cancer: a perspective.

Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis.

Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading.

Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy.

The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies.

A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy.

Gleason scoring: a comparison of classical and modified (international society of urological pathology) criteria using nadir PSA as a clinical end point.

P304

1346-1352

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/PAS.0B013E3182556DCD

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22531173

http://www.w3.org/2001/XMLSchema#string

P921

P932

3421030

http://www.w3.org/2001/XMLSchema#string